ArticleAntimicrobial agents and chemotherapy2026
Bedaquiline reloading strategies following interruptions during daily dosing.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Once-daily bedaquiline therapy is a WHO-listed alternative to thrice-weekly dosing for rifampicin-resistant tuberculosis, but, contrary to the thrice-weekly schedule, no guidance exists for treatment re-initiation after interruption. Using a population pharmacokinetic model, we simulated bedaquiline and M2 exposure under various interruption and reloading scenarios. Reloading strategies tailored to interruption duration restored bedaquiline exposure without clinically relevant increases in M2 peak concentrations, providing practical guidance for safe and effective treatment resumption of once-daily bedaquiline therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.